Why Most Countries Won't Benefit From Moderna And Pfizer’s Covid-19 Vaccines

That the Moderna and Pfizer Covid-19 vaccines demonstrated efficacy in more than 90 percent of phase 3 trial participants is cause for celebration. Developed at breakneck speed with heretofore unrealized mRNA technology, they have without a doubt made history, especially now that the British government has authorized the Pfizer vaccine for mass use. The problem—and regrettably, it is a big one—is that only a very small fraction of the global population will be able to reap the rewards of this achievement. To remain stable, the Pfizer vaccine must be stored in specialized freezers kept at an ultra-low temperature of negative 94 degrees Fahrenheit. Such storage units are manufactured at a select few “freezer farms” and priced at $10,000 to $15,000 apiece.  While the Moderna vaccine doesn’t demand as deep a freeze—the requisite negative 4 degrees Fahrenheit is comparable to a standard home freezer—both must be administered in two doses a month apart, a logistical hurdle not uncommon but certainly not ideal in a quest for worldwide inoculation. Read full article in Forbes Originally published in Forbes (December 2, 2020)
© William A. Haseltine, PhD. All Rights Reserved.